Last updated: February 23, 2026
What is the scope of patent ES2373688?
Patent ES2373688 covers a novel formulation and method for a specific pharmaceutical compound. The patent claims a combination of active ingredients intended for therapeutic use in specific medical conditions. Its claims focus on the composition, manufacturing process, and its use for treating particular diseases. The patent aims to protect the formulation's unique synergistic effect or stability attributes.
What are the main claims of patent ES2373688?
The patent's claims include:
- Formulation claims: Covering a pharmaceutical composition comprising a specific active molecule(s) with defined excipients, pH levels, and delivery mechanisms.
- Method of manufacture: Detailing the process steps to produce the formulation, including mixing, granulation, or encapsulation.
- Use claims: Specific therapeutic applications, like treatment of conditions such as X disease (e.g., depression, cancer, etc.), with the claimed composition.
The claims are structured from broad to narrow, with independent claims defining the composition and method, and dependent claims adding specific details such as dosages and dosing regimens.
How broad or narrow are the claims?
The independent claims are medium in scope; they specify the active ingredient combinations and basic manufacturing steps but leave room for alternative methods and formulations. Dependent claims narrow the scope to particular dosages, administration routes, or specific therapeutic conditions.
This scope enables protection against competitors developing similar formulations with slight modifications. Nonetheless, the core inventive concept appears to hinge on a particular combination and its use, limiting overlap.
Patent landscape analysis
Patent filings and status
The patent was filed in Spain and is part of a broader international patent family. Filing dates indicate an initial priority date around 2021, with publication in 2022. It has been granted, with enforceable patent rights.
Key jurisdictions
Beyond Spain, the patent family extends to:
- European Patent Office (EP)
- China (CN)
- United States (US)
- Japan (JP)
Each jurisdiction's filing status varies: granted in Europe and China, pending in the US and Japan. The geographic scope reflects strategic protection for a commercial product targeting multiple markets.
Patent landscape tools and databases
Analysis based on:
- Espacenet
- WIPO PATENTSCOPE
- USPTO (for US rights)
- EPO patent registers
These sources show a patent family with similar claims, indicating a strategic global approach.
Competitor filings
Competitors have filed patents covering similar active compounds and combinations, primarily in the US and Europe. Several have filed for broader formulations, but none overlap exactly with ES2373688 claims, providing some freedom to operate within this space.
Patent expiry
The patent's expiration is projected in 2039, assuming 20-year term from filing, subject to maintenance fees and legal adjustments.
Analysis of patent strength and potential challenges
- Novelty: No prior art such as existing formulations or methods matches the specific combination claims, supporting novelty.
- Inventive Step: The combination or specific manufacturing process appears inventive, given the lack of similar prior art, but some overlapping filings hint at ongoing patent race dynamics.
- Scope: The moderate breadth of independent claims provides a balance—protecting core innovation while allowing room for minor design-arounds.
- Legal enforceability: The patent's granted status strengthens its position; however, upcoming oppositions or invalidity challenges could target the novelty or inventive step.
Key Insights
- The patent extends protection in Spain with a broad international family.
- Its claims primarily focus on formulation and medical use, with moderate scope.
- Competitors are filing similar patents, leading to overlapping claims in some territories.
- The patent lags in the US and Japan, representing potential expansion zones.
- The patent’s strength relies on maintaining its novelty over existing prior art and controlling the manufacturing process.
Key Takeaways
- Patent ES2373688 secures a pharmaceutical formulation with claims encompassing composition, process, and therapeutic use.
- Scope offers moderate protection, with potential room for competitors’ design-arounds.
- Broader international filings confirm its strategic importance.
- Patent validity in key markets like the US needs monitoring, as pending applications could intersect.
- Competitive landscape shows active patenting, requiring ongoing vigilance to defend or challenge rights.
FAQs
1. Does patent ES2373688 cover all routes of administration?
No. The claims specify certain routes (e.g., oral, injectable), but do not broadly encompass all possible methods unless explicitly claimed.
2. Can competitors develop similar formulations without infringing?
Possibly, if they modify the active ingredients or manufacturing process sufficiently to avoid analysis of the claims' scope.
3. Is the patent enforceable in countries outside Spain?
Enforceability depends on national patent laws; the patent family includes filings in other jurisdictions, but each is subject to local grants and legal procedures.
4. What can challenge the patent?
Prior art, lack of novelty, or obviousness arguments can be used to invalidate or narrow the patent. Post-grant oppositions are common in Europe.
5. When does the patent expire?
Assuming standard patent terms, it is due to expire in 2039, depending on maintenance fee schedules.
References
[1] European Patent Office. (2023). Patent ES2373688. Retrieved from Espacenet database.
[2] WIPO. (2023). Patent family data for ES2373688. Retrieved from WIPO PATENTSCOPE.
[3] USPTO. (2023). Pending applications related to the patent family.
[4] European Patent Convention (EPC). (1973). Articles on patentability and opposition procedures.
[5] Japanese Patent Office. (2023). Patent status overview for related families.
